Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

NCT07301008 is registered in ClinicalTrials.gov with Medstar Health Research Institute as lead sponsor.

NCT NCT07301008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Lead sponsor
Medstar Health Research Institute
Phase
Phase 4
Overall status
Recruiting
Start date
September 9, 2025
Completion date
January 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, trigger induced migraine